Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double-Blind, Placebo-Controlled Parallel Multi-Center Study to Assess the Efficacy of Cannabidiol (BRCX014) Combined With Standard-Of-Care Treatment in Subjects With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

NCT03607643 is registered in ClinicalTrials.gov with Leaf Vertical Inc. as lead sponsor.

NCT NCT03607643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03607643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double-Blind, Placebo-Controlled Parallel Multi-Center Study to Assess the Efficacy of Cannabidiol (BRCX014) Combined With Standard-Of-Care Treatment in Subjects With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Lead sponsor
Leaf Vertical Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 15, 2019
Completion date
December 15, 2020
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of colon, cancer of liver, cancer of pancreas, cancer of rectum, cancer, gall bladder, glioblastoma multiforme, myeloma multiple